Cargando…

532. Recurrent C. difficile in Children: Not Easy to Cure

BACKGROUND: Little is known about the clinical characteristics and appropriate treatment of children with repeated C. difficile infections (rCDI). Current IDSA treatment recommendations for rCDI include oral vancomycin (VAN) or metronidazole (MTZ) based on weak/low-quality evidence. METHODS: We perf...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Philip, Aroniadis, Olga, Noble, Sarah, Rimawi, Fatimah, Goldman, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255573/ http://dx.doi.org/10.1093/ofid/ofy210.541

Ejemplares similares

2396. Clostridium difficile Infection is Children with Sickle Cell Disease: An Uncommon Entity
por: Lee, Philip, et al.
Publicado: (2019)

Heterogeneity of Randomized Controlled Trials of Fecal Microbiota Transplantation in Recurrent Clostridioides difficile Infection
por: Feuerstadt, Paul, et al.
Publicado: (2021)

Very low incidence of Clostridioides difficile infection in pediatric sickle cell disease patients
por: Lee, Philip, et al.
Publicado: (2020)

507. Degree of Concordance of Clostridium difficile Strains in Adults with Community-Associated C. difficile Infection and Infants With C. difficile Colonization
por: Clayton, Jason A, et al.
Publicado: (2018)

627. Differences in C. difficile Toxin A Binding in Humans: Adults vs. Infants
por: Goldman, David, et al.
Publicado: (2018)

Clostridium difficile Molecular Epidemiology in a Prospective Cohort of Canadian Children Compared with Cases of C. difficile Infection
por: Lloyd, Colin, et al.
Publicado: (2017)

532. Nirmatrelvir/Ritonavir Versus Placebo in Unvaccinated and Vaccinated High Risk Patients
por: Leister-Tebbe, Heidi, et al.
Publicado: (2023)

Endogenous Serum IgG Antibodies to Clostridium difficile Toxin B Are Associated with Protection against C. difficile Infection Recurrence
por: Kelly, Ciaran P, et al.
Publicado: (2017)

Metabolic Profiling of Human In-patient Stools: The Influence of C. difficile Infection and Recurrence
por: Yacyshyn, Mary Beth, et al.
Publicado: (2017)

Microbiome predictors of dysbiosis and VRE decolonization in patients with recurrent C. difficile infections in a multi-center retrospective study
por: Santiago, Marina, et al.
Publicado: (2019)

Cholesterol cure made easy
por: Lewis, Sylvan R.
Publicado: (1994)

508. High Rates of Cure and Long-Term Symptom Resolution With Both Capsule and Lower Gastrointestinal Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection
por: Shull, Hannah, et al.
Publicado: (2018)

619. Intestinal Microbiome Changes Associated with Immune Status and Clostridium difficile Colonization in Hospitalized Children
por: Mohandas, Sindhu, et al.
Publicado: (2018)

663. Epidemiology and outcomes of recurrent C. difficile infection among hematopoietic cell transplant recipients
por: Sanchez, Eduardo, et al.
Publicado: (2023)

Comparison of Fidaxomicin and Vancomycin for Recurrent Clostridium difficile Colitis
por: Khoo, Teresa, et al.
Publicado: (2017)

400. Rehospitalization of Patients for Recurrent Clostridioides difficile Infection
por: Drwiega, Emily, et al.
Publicado: (2022)

532 Maximum Expiratory Flow in Health Children from the Metropolitan Area of Monterrey Mexico
por: Valdes, Dora, et al.
Publicado: (2012)

657. Impact of Oral Vancomycin Duration on Clostridioides difficile Recurrence in Patients Requiring Concurrent Systemic Antibiotics
por: Marsh, Kassandra, et al.
Publicado: (2023)

532. Can Saccharomyces boulardii Therapy Be Effective in Decolonizing Rectal Carbapenem-Resistant Enterobacteriaceae (CRE) Colonization?
por: Resat Sipahi, Oguz, et al.
Publicado: (2019)

Prospective, Open-label Trial to Evaluate Efficacy of Lyophilized Fecal Microbiota Transplantation for Treatment of Recurrent C. difficile Infection
por: Goldeh, Peyman, et al.
Publicado: (2017)

532. COVID-19 Pneumonia in Patients with Hematologic Malignancies – A Report from the US Epicenter
por: Plate, Markus, et al.
Publicado: (2020)

Risk Factors for Recurrent Pedatric Community Associated Clostridium difficile Infection
por: Parmar, Deepika, et al.
Publicado: (2017)

Lyophilized Fecal Microbiota Transplantation Capsules for Recurrent Clostridium difficile Infection
por: Dupont, Hebert, et al.
Publicado: (2017)

Engraftment and Augmentation of Microbiome Following Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection
por: Lee, Christine, et al.
Publicado: (2017)

Durability and Long-Term Clinical Outcomes of Fecal Microbiota Transplant (FMT) Treatment in Patients with Recurrent C. difficile Infection
por: Mamo, Yafet, et al.
Publicado: (2017)

135. Impact of Clostridioides difficile Toxin Confirmation on Subsequent C. difficile Treatment in a Rural Health System (IT-CDI)
por: Crawford, Jacquelyn, et al.
Publicado: (2023)

Enzyme Immunoassay for C. difficile Toxin Reduces Lab ID Events but Fails to Detect Clinically Significant C. difficile Infection
por: Ridgway, Jessica P, et al.
Publicado: (2017)

PM532. Symptomatic Remission and Functional Recovery after Paliperidone Palmitate 3-monthly or 1-monthly treatment in Asian Patients with Exacerbated Schizophrenia
por: Savitz, Adam, et al.
Publicado: (2016)

670. VRE Clearance in Patients with Recurrent Clostridium difficile Infection Following Treatment with Microbiota-Based Drug RBX2660
por: Hau, Heidi, et al.
Publicado: (2019)

390. Eravacycline combination therapy for severe, recurrent, or fulminant Clostridioides difficile infection
por: Morrison, Austin R, et al.
Publicado: (2022)

679. Retrospective Analysis of Vancomycin and Fidaxomicin for the Treatment of Recurrent Clostridioides difficile Infection
por: Fabian, Amy, et al.
Publicado: (2023)

669. Twelve-Month Durability of Microbiota-Based Therapy RBX2660 for Prevention of Recurrent Clostridium difficile Infection
por: Jones, Courtney, et al.
Publicado: (2019)

1631 The Impact of Obesity of Clostidium difficile Recurrence
por: Lou, Uvette, et al.
Publicado: (2014)

501. Evaluation of Bezlotoxumab in Prevention of Recurrent C. difficile Infection: A Multicenter Single-Arm Study in Outpatient Infusion Centers
por: Hengel, Richard L, et al.
Publicado: (2018)

787. Evaluation of Clostridioides difficile Environmental Contamination Surrounding C. difficile Patients vs. non-C. difficile Patients in Outpatient Infusion Centers
por: Garey, Kevin W, et al.
Publicado: (2020)

500. Efficacy of 30-Day Fidaxomicin for Treatment of Acute Clostridium difficile Infection With History of Multiple Recurrences
por: Lee, Christine, et al.
Publicado: (2018)

495. Predictors of C. difficile Infection and Impact of Primary Prophylaxis Among Asymptomatic C. difficile Colonized Patients: A Cross-Sectional Study
por: Poirier, Dominic, et al.
Publicado: (2018)

729. Real World Efficacy of Bezlotoxumab for Prevention of Clostridioides Difficile Recurrence in Immunosuppressed Patients
por: Perreault, Sarah, et al.
Publicado: (2020)

502. Enhanced Sporulation and Vancomycin Resistance Associated With Clostridium difficile From Recurrent Infections
por: Tijerina-Rodriguez, Laura E, et al.
Publicado: (2018)

687. Zinplava Expert Retrospective Observations (ZERO) Study Findings on Clostridioides difficile Recurrence
por: Jacobs, Micah, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6p0egiv41ktjgbd4uqqmumeaj2